{"organizations": [], "uuid": "8006158fe7d35cea7c39c9483a9b77c5f8cd8d45", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180212.html", "section_title": "Archive News &amp; Video for Monday, 12 Feb 2018 | Reuters.com", "url": "https://www.reuters.com/article/axovant-sciences-moves-ceo/drug-developer-axovants-ceo-coo-step-down-idUSL4N1Q2417", "country": "US", "domain_rank": 408, "title": "Drug developer Axovant's CEO, COO step down", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-02-12T20:16:00.000+02:00", "replies_count": 0, "uuid": "8006158fe7d35cea7c39c9483a9b77c5f8cd8d45"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/axovant-sciences-moves-ceo/drug-developer-axovants-ceo-coo-step-down-idUSL4N1Q2417", "ord_in_thread": 0, "title": "Drug developer Axovant's CEO, COO step down", "locations": [], "entities": {"persons": [{"name": "axovant", "sentiment": "negative"}, {"name": "david hung", "sentiment": "negative"}, {"name": "manas mishra", "sentiment": "none"}, {"name": "marion mccourt", "sentiment": "none"}, {"name": "maju samuel", "sentiment": "none"}, {"name": "pavan cheruvu", "sentiment": "none"}], "locations": [{"name": "bengaluru", "sentiment": "none"}], "organizations": [{"name": "coo", "sentiment": "negative"}, {"name": "axovant sciences ltd", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Feb 12 (Reuters) - Axovant Sciences Ltd on Monday said Chief Executive Officer David Hung had resigned, nearly a year after his appointment.\nChief Operating Officer Marion McCourt has also stepped down, along with three members of the drug developerâ€™s board.\nThe company named Pavan Cheruvu as its new CEO. (Reporting by Manas Mishra in Bengaluru; Editing by Maju Samuel)\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-02-12T20:16:00.000+02:00", "crawled": "2018-02-13T15:54:32.004+02:00", "highlightTitle": ""}